… in improving the efficacy of erlotinib. The Cancer and Leukemia Group B trial 30406 was
a randomized phase 2 clinical trial that investigated erlotinib alone or with carboplatin and …

… We hypothesized that erlotinib would be efficacious in the adjuvant setting. … The efficacy
of a lower dose of erlotinib has not been studied prospectively in a randomized trial in patients …

Purpose A multicenter randomized phase II trial to evaluate two treatment strategies in the
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …

… for the erlotinib group and 11·5 months for the placebo group, median PFS was significantly
longer with erlotinib than with placebo: 12·3 weeks for patients in the erlotinib group versus …

… To some extent, the conclusion of the present study was almost the same as that of the
earlier randomised phase II study, in which gefitinib and erlotinib showed similar efficacy and …

… The potential for combining EGFR TKIs with cytotoxic drugs was initially investigated in four
randomized phase III trials. In these studies, concurrent administration of erlotinib or gefitinib …

… and in combination with erlotinib; it demonstrated a … , randomized phase II trial to prospectively
compare the progression-free survival (PFS) of erlotinib plus tivantinib with erlotinib plus …

… Our prospective, randomized phase II study of patients with NSCLC who previously … that
demonstrated entinostat combined with erlotinib enhances the effect of erlotinib alone and can …

… of TKI therapy, randomized trials evaluating the role of continuing these drugs beyond
progression are desperately needed. In 2007, we initiated a randomized phase II study to assess …

… , randomized phase II trial examined the efficacy and safety of combination erlotinib plus
fulvestrant compared to erlotinib … Although there was no improvement in PFS or OS with erlotinib …